86 related articles for article (PubMed ID: 19332728)
1. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
Goekkurt E; Al-Batran SE; Hartmann JT; Mogck U; Schuch G; Kramer M; Jaeger E; Bokemeyer C; Ehninger G; Stoehlmacher J
J Clin Oncol; 2009 Jun; 27(17):2863-73. PubMed ID: 19332728
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.
Smyth E; Zhang S; Cunningham D; Wotherspoon A; Soong R; Peckitt C; Valeri N; Fassan M; Rugge M; Okines A; Allum W; Stenning S; Nankivell M; Langley R; Tan P
Clin Cancer Res; 2017 Dec; 23(24):7543-7549. PubMed ID: 28972045
[No Abstract] [Full Text] [Related]
3. Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance).
Patel JN; Jiang C; Owzar K; Mulkey F; Luzum JA; Mamon HJ; Haller DG; Dragovich T; Alberts SR; Bjarnason G; Willet CG; Niedzwiecki D; Enzinger P; Ratain MJ; Fuchs C; McLeod HL
Pharmacogenet Genomics; 2021 Dec; 31(9):215-220. PubMed ID: 34149004
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.
Tecza K; Pamula-Pilat J; Lanuszewska J; Butkiewicz D; Grzybowska E
Oncotarget; 2018 Feb; 9(10):9114-9136. PubMed ID: 29507678
[TBL] [Abstract][Full Text] [Related]
5. Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review.
Afifah NN; Diantini A; Intania R; Abdulah R; Barliana MI
Pharmgenomics Pers Med; 2020; 13():427-444. PubMed ID: 33116759
[TBL] [Abstract][Full Text] [Related]
6. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.
McWhinney-Glass S; Winham SJ; Hertz DL; Yen Revollo J; Paul J; He Y; Brown R; Motsinger-Reif AA; McLeod HL;
Clin Cancer Res; 2013 Oct; 19(20):5769-76. PubMed ID: 23963862
[TBL] [Abstract][Full Text] [Related]
7. Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review.
Zazuli Z; Vijverberg S; Slob E; Liu G; Carleton B; Veltman J; Baas P; Masereeuw R; Maitland-van der Zee AH
Front Pharmacol; 2018; 9():1111. PubMed ID: 30319427
[No Abstract] [Full Text] [Related]
8. Association between Genetic Variants and Peripheral Neuropathy in Patients with NSCLC Treated with First-Line Platinum-Based Therapy.
de Jong C; Herder GJM; van Haarlem SWA; van der Meer FS; van Lindert ASR; Ten Heuvel A; Brouwer J; Egberts TCG; Deneer VHM
Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672910
[TBL] [Abstract][Full Text] [Related]
9. Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity.
Pozzi E; Alberti P
Methods Mol Biol; 2022; 2547():95-140. PubMed ID: 36068462
[TBL] [Abstract][Full Text] [Related]
10. Genome-Wide Analyses of Nephrotoxicity in Platinum-Treated Cancer Patients Identify Association with Genetic Variant in
Klumpers MJ; Witte W; Gattuso G; Schiavello E; Terenziani M; Massimino M; Gidding CEM; Vermeulen SH; Driessen CM; Van Herpen CM; Van Meerten E; Guchelaar HJ; Coenen MJH; Te Loo DMWM
J Pers Med; 2022 May; 12(6):. PubMed ID: 35743677
[TBL] [Abstract][Full Text] [Related]
11. Single nucleotide polymorphisms as the new predictors of therapy decisions in gastroesophageal junction and gastric adenocarcinoma?
Schulz C; Stintzing S
Transl Cancer Res; 2020 Apr; 9(4):2175-2177. PubMed ID: 35117577
[No Abstract] [Full Text] [Related]
12. Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study.
Zazuli Z; de Jong C; Xu W; Vijverberg SJH; Masereeuw R; Patel D; Mirshams M; Khan K; Cheng D; Ordonez-Perez B; Huang S; Spreafico A; Hansen AR; Goldstein DP; de Almeida JR; Bratman SV; Hope A; Knox JJ; Wong RKS; Darling GE; Kitchlu A; van Haarlem SWA; van der Meer F; van Lindert ASR; Ten Heuvel A; Brouwer J; Ross CJD; Carleton BC; Egberts TCG; Herder GJM; Deneer VHM; Maitland-van der Zee AH; Liu G
J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834585
[TBL] [Abstract][Full Text] [Related]
13. A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
Cordova-Delgado M; Bravo ML; Cumsille E; Hill CN; Muñoz-Medel M; Pinto MP; Retamal IN; Lavanderos MA; Miquel JF; Rodriguez-Fernandez M; Liao Y; Li Z; Corvalán AH; Armisén R; Garrido M; Quiñones LA; Owen GI
BMC Cancer; 2021 Sep; 21(1):1030. PubMed ID: 34525956
[TBL] [Abstract][Full Text] [Related]
14. Genetic Predictors of Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel, Carboplatin and Oxaliplatin: NCCTG/Alliance N08C1, N08CA and N08CB Study.
Adjei AA; Lopez CL; Schaid DJ; Sloan JA; Le-Rademacher JG; Loprinzi CL; Norman AD; Olson JE; Couch FJ; Beutler AS; Vachon CM; Ruddy KJ
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33802509
[TBL] [Abstract][Full Text] [Related]
15. Identification of Novel Biomarkers for Predicting Kidney Injury Due to Drugs Using "Omic" Strategies.
Awdishu L; Atilano-Roque A; Tuey S; Joy MS
Pharmgenomics Pers Med; 2020; 13():687-705. PubMed ID: 33293850
[TBL] [Abstract][Full Text] [Related]
16. Glutathione S-transferase Polymorphisms in Head and Neck Squamous Cell Carcinoma Treated with Chemotherapy and/or Radiotherapy.
Maniglia MP; Russo A; Biselli-Chicote PM; Oliveira-Cucolo JG; Rodrigues-Fleming GH; -Maniglia JV; Pavarino ÉC; Goloni-Bertollo EM
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1637-1644. PubMed ID: 32592358
[TBL] [Abstract][Full Text] [Related]
17. ABCB1 and ERCC1 gene polymorphisms are associated with nephro- and hepatotoxicity to carboplatin/paclitaxel-based chemotherapy in patients with gynecologic cancers.
da Costa Junior LC; de Castro CL; Freitas-Alves DR; Vianna-Jorge R; Santos PCJL
Eur J Clin Pharmacol; 2020 Oct; 76(10):1401-1408. PubMed ID: 32564116
[TBL] [Abstract][Full Text] [Related]
18. Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines.
Wang XZ; Zeng ZY; Ye X; Sun J; Zhang ZM; Kang WM
World J Gastrointest Oncol; 2020 Jan; 12(1):37-53. PubMed ID: 31966912
[TBL] [Abstract][Full Text] [Related]
19. Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies.
Butters O; Young K; Cunningham D; Chau I; Starling N
Front Oncol; 2019; 9():618. PubMed ID: 31380271
[TBL] [Abstract][Full Text] [Related]
20. Glutathione S-transferases genes variants and chemotherapy efficacy in gastrointestinal cancer patients: a meta-analysis based on 50 pharmacogenetic studies.
Sun Y; Pan J; Tong X; Chen E; Yan W; Wu M; Qu Q; Qu J
J Cancer; 2019; 10(13):2915-2926. PubMed ID: 31281468
[No Abstract] [Full Text] [Related]
[Next] [New Search]
